No conflicts of interest were declared.
1096-9896/asset/PATH_left.gif?v=1&s=f8845e760fcc5be3e3baa6119dcc01c077e3db22)
1096-9896/asset/PATH_right.gif?v=1&s=86062495907b9532cd169b5a6605dac7fd14f581)
Invited Review
Network-based drugs and biomarkers†
Article first published online: 17 NOV 2009
DOI: 10.1002/path.2646
Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Issue
The Journal of Pathology
Special Issue: Genes, Genomes and Disease
Volume 220, Issue 2, pages 290–296, January 2010
Additional Information
How to Cite
Erler, J. T. and Linding, R. (2010), Network-based drugs and biomarkers. The Journal of Pathology, 220: 290–296. doi: 10.1002/path.2646
- †
Publication History
- Issue published online: 7 DEC 2009
- Article first published online: 17 NOV 2009
- Manuscript Accepted: 5 OCT 2009
- Manuscript Revised: 4 OCT 2009
- Manuscript Received: 16 SEP 2009
Keywords:
- systems biology;
- gene;
- network;
- biomarker;
- treatment;
- drug;
- signalling
Abstract
The structure and dynamics of protein signalling networks governs cell decision processes and the formation of tissue boundaries. Complex diseases such as cancer and diabetes are diseases of such networks. Therefore approaches that can give insight into how these networks change during disease progression are crucial for better understanding, detection and intervention. The era of network medicine has begun; however, there are fundamental principles associated with molecular networks that are essential to consider for this field to succeed. Here, we introduce network biology and some of its associated technologies. We then focus on the multivariate nature of cellular networks and how this has implications for biomarker and drug discovery using cancer metastasis as an example. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.